148 related articles for article (PubMed ID: 25611107)
1. Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population.
Alameda F; Garrote L; Mojal S; Sousa C; Muset M; LLoveras B; Bellosillo B; Saldanha C; Carreras R; Serrano S
Arch Pathol Lab Med; 2015 Feb; 139(2):241-4. PubMed ID: 25611107
[TBL] [Abstract][Full Text] [Related]
2. A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off.
Boehmer G; Wang L; Iftner A; Holz B; Haedicke J; von Wasielewski R; Martus P; Iftner T
BMC Infect Dis; 2014 Dec; 14():674. PubMed ID: 25487281
[TBL] [Abstract][Full Text] [Related]
3. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
[TBL] [Abstract][Full Text] [Related]
4. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.
Poljak M; Kovanda A; Kocjan BJ; Seme K; Jancar N; Vrtacnik-Bokal E
Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep; 18(3):94-103. PubMed ID: 19784522
[TBL] [Abstract][Full Text] [Related]
5. Clinical Validation of Anyplex II HPV HR Detection Test for Cervical Cancer Screening in Korea.
Jung S; Lee B; Lee KN; Kim Y; Oh EJ
Arch Pathol Lab Med; 2016 Mar; 140(3):276-80. PubMed ID: 26927723
[TBL] [Abstract][Full Text] [Related]
6. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
[TBL] [Abstract][Full Text] [Related]
7. Clinical performance characteristics of the Cervista HPV HR test kit in cervical cancer screening in China.
Zhao J; Zhang X; Ma J; Liu G; Yao D; Zhang W; Wang J; Wei L; Zhao Y; Zeng Y; Liao Q
J Low Genit Tract Dis; 2012 Oct; 16(4):358-63. PubMed ID: 23023138
[TBL] [Abstract][Full Text] [Related]
8. Rate of detection of high-risk HPV with two assays in women ≥ 30 years of age.
Quigley NB; Potter NT; Chivukula M; Knight MZ; Welch JR; Olson MC
J Clin Virol; 2011 Sep; 52(1):23-7. PubMed ID: 21724457
[TBL] [Abstract][Full Text] [Related]
9. Clinical performance of hybrid capture 2 human papillomavirus testing for recurrent high-grade cervical/vaginal intraepithelial neoplasm in patients with an ASC-US Papanicolaou test result during long-term posttherapy follow-up monitoring.
De Vivar AD; Dawlett M; Wang JP; Jack A; Gong Y; Staerkel G; Guo M
Arch Pathol Lab Med; 2015 Feb; 139(2):219-24. PubMed ID: 25611104
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Aptima and Cervista tests for detection of high-risk human papillomavirus in cervical cytology specimens.
Nolte FS; Ribeiro-Nesbitt DG
Am J Clin Pathol; 2014 Oct; 142(4):561-6. PubMed ID: 25239425
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of The Cervista HPV A9 group In Screening Patients for Cervical Cancer.
Zhao J; Du H; Belinson JL; Qu X; Zhang W; Mei J; Yang B; Wang C; Zhang L; Wu R
J Med Screen; 2016 Mar; 23(1):38-43. PubMed ID: 26466824
[TBL] [Abstract][Full Text] [Related]
12. Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off.
Boers A; Slagter-Menkema L; van Hemel BM; Belinson JL; Ruitenbeek T; Buikema HJ; Klip H; Ghyssaert H; van der Zee AG; de Bock GH; Wisman GB; Schuuring E
PLoS One; 2014; 9(7):e101930. PubMed ID: 25051098
[TBL] [Abstract][Full Text] [Related]
13. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
[TBL] [Abstract][Full Text] [Related]
14. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].
Li RZ; Shi JF; Zhou QZ; Wu RF; Li N; Wu LN; Zhou YQ; Wang Q; Liu ZH; Liu B; Qiao YL
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(5):307-11. PubMed ID: 16677522
[TBL] [Abstract][Full Text] [Related]
16. Clinical validation of the Cervista HPV HR test according to the international guidelines for human papillomavirus test requirements for cervical cancer screening.
Boers A; Wang R; Slagter-Menkema L; van Hemel BM; Ghyssaert H; van der Zee AG; Wisman GB; Schuuring E
J Clin Microbiol; 2014 Dec; 52(12):4391-3. PubMed ID: 25297324
[TBL] [Abstract][Full Text] [Related]
17. Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: outcome comparison in women with negative cervical cytology.
Kurian EM; Caporelli ML; Baker S; Woda B; Cosar EF; Hutchinson L
Am J Clin Pathol; 2011 Nov; 136(5):808-16. PubMed ID: 22031321
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of careHPV, Cervista Human Papillomavirus, and Hybrid Capture 2 Methods in Diagnosing Cervical Intraepithelial Neoplasia Grade 2+ in Xinjiang Uyghur Women.
Tuerxun G; Yukesaier A; Lu L; Aierken K; Mijiti P; Jiang Y; Abulizi A; Zhang Y; Abuduxikuer G; Abulizi G; Li H
Oncologist; 2016 Jul; 21(7):825-31. PubMed ID: 27317575
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of the cervista and hybrid capture 2 methods in detecting high-risk human papillomavirus in cervical lesions.
Tao K; Yang J; Yang H; Guo ZH; Hu YM; Tan ZY; Zhang F; Duan JL
Diagn Cytopathol; 2014 Mar; 42(3):213-7. PubMed ID: 23904341
[TBL] [Abstract][Full Text] [Related]
20. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
